Barclays PLC Raises Position in OPKO Health, Inc. (NASDAQ:OPK)

Barclays PLC grew its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 154.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 543,336 shares of the biotechnology company’s stock after purchasing an additional 329,870 shares during the quarter. Barclays PLC’s holdings in OPKO Health were worth $810,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Orion Portfolio Solutions LLC purchased a new position in OPKO Health in the 3rd quarter worth approximately $45,000. XTX Topco Ltd lifted its stake in OPKO Health by 166.5% in the 3rd quarter. XTX Topco Ltd now owns 108,652 shares of the biotechnology company’s stock worth $162,000 after purchasing an additional 67,883 shares in the last quarter. Point72 DIFC Ltd purchased a new position in OPKO Health in the 3rd quarter worth approximately $71,000. Clearline Capital LP purchased a new position in OPKO Health in the 3rd quarter worth approximately $1,083,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in OPKO Health in the 3rd quarter worth approximately $138,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on OPK. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, January 8th. StockNews.com lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a research report on Wednesday. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Friday, November 8th.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average cost of $1.56 per share, with a total value of $780,000.00. Following the transaction, the chief executive officer now owns 212,411,477 shares in the company, valued at approximately $331,361,904.12. This trade represents a 0.24 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders bought 1,804,255 shares of company stock valued at $2,764,605. Insiders own 47.26% of the company’s stock.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.47 on Thursday. The company has a fifty day simple moving average of $1.54 and a two-hundred day simple moving average of $1.50. The company has a market cap of $1.00 billion, a price-to-earnings ratio of -7.74 and a beta of 1.62. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health, Inc. has a 52 week low of $0.86 and a 52 week high of $1.76.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.